Pancreatic cancer pill daraxonrasib shows survival boost in ASCO data
TL;DR Summary
ASCO data show Revolution Medicines’ oral daraxonrasib, a molecular glue that blocks RAS, delaying cancer symptoms by more than nine months and extending median survival to 13.2 months in advanced pancreatic cancer; while not curative, it improves length and quality of life versus chemotherapy, with side effects like rash and mouth sores that are usually manageable.
- Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows | World News Hindustan Times
- After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses NBC News
- This Pancreatic Cancer Drug Is So Good, It Got a Standing Ovation Bloomberg.com
- Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO 2026: A Game-Changer Oncology News Central
- Daily pill can double survival time for world’s deadliest cancer, trial shows | Pancreas cancer The Guardian
Reading Insights
Total Reads
0
Unique Readers
7
Time Saved
24 min
vs 25 min read
Condensed
99%
4,806 → 56 words
Want the full story? Read the original article
Read on Hindustan Times